# Ilika commercial demand is very strong (LON:IKA)

- Link: https://www.directorstalkinterviews.com/ilika-commercial-demand-is-very-strong-lonika/4121073405
- Published: 2022-07-19T07:44:00+01:00
- Author: Amilia Stone

**[Ilika plc](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l) (
[LON:IKA](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)) **Chief
Executive Officer Graeme Purdy caught** **up with DirectorsTalk for an exclusive
interview to discuss their Stereax tech transfer, process qualification, commercial
demand, how the £24 million will be deployed, the scale up risk for Goliath and 
succeeding against well-funded competitors.

**Q1: ****Could you give us an overview of the progress that you’re making with 
your Stereax tech transfer to your fab?**

**A1**: Well, it’s been a very intense year of tech transfer.

We have moved our technology from our pilot line where we’ve been making small quantities
of Stereax cells for release to customers over the past few years and we had a successful
implementation of our new fab actually in what was a very challenging year in terms
of disruption to the supply chain globally.

Our vendors and contractors have done very well in delivering the facility and in
December of 2021, we had the official opening of the facility by our local MP, Steve
Brine and since then we’ve been qualifying the process, getting ready for scale 
up and production.

**Q2: Now, the Stereax process qualification has taken longer than you anticipated
last year. What were the challenges?**

**A2**: Yes, that’s right. We were hoping that we would be able to follow the legendary
Intel mantra of copy exactly in order to implement our process at the fab. Of course
we had the benchmark process conditions from our pilot line that we were able to
refer to, but of course, in order to get the advantages of scale, we had to re-engineer
some of the process steps in order to deploy larger scale equipment which was capable
of giving a higher throughput of production.

Unfortunately we found that one of the steps, which is our reactive evaporative 
deposition step, which is the step that we use actually for making our cathode material,
so our positive electrodes in the batteries, the equipment that we’d specified didn’t
use the same process conditions as those that we’d use successfully on the pilot
line. So by that, I mean, things like the pressure, temperature and deposition rates
of the sources that that piece of equipment uses.

So, we ended up having to run a design of experiments, or a DOE as it’s referred
to, in order to define the operating window so that we could get the quality of 
products that we were looking for.

**Q3: How confident are you in the commercial demand for Stereax?**

**A3**: Commercial demand is very strong. We have a portfolio of customers who are
waiting, some of them patiently, some of them impatiently understandably, for delivery
of the product and they all have their own product development programmes that they’re
looking to feed our batteries into. So, we need to make sure that we try and synchronise
our production activities as closely as possible to their needs.

A lot of our customers are in the miniature medical implant space so there’s some
very interesting applications there, a lot of them with very high volumes in the
mass market. What we need to do is work together with them in order to ramp up production
over the coming years, across that portfolio, in order to get to the mass market
volumes ultimately that the markets are going to demand.

The idea is that actually we use our mid-scale fab that we’ve got here in the UK
in order to support the early years of product approval, through pre-clinical activities
and then into clinical trials and approval and initial product launch. Because a
lot of the applications actually involve selling into markets that even individually
are larger than the full capacity of our fab, there will be another tech transfer
step either directly to the OEM or to one of their outsource partners in order to
be able to sustain the ramp up beyond what the capacity of our fab is.

**Q4: Last year you raised £24 million to support the Goliath EV battery programme.
How are you deploying those funds?**

**A4**: We said at the time, actually that about £5 million of those funds was going
to be used for equipment in order to automate the pre-pilot line that we’ve got 
at our Goliath development facility. About £10 million would be used for supporting
the further development of the Goliath product so effectively paying for the R&D
team and the expenses that they incur and that’s what we’re doing.

We’re very much following that investment programme and progress has been very gratifying,
actually we can see ourselves moving up the development curve, moving up the S curve
in terms of energy density and power density for Goliath.

So, that feels very much on track.

**Q5: Just talking about curves, how are you managing the scale up risk for Goliath?**

**A5**: So, there are some proprietary elements to the process that we’re using 
for Goliath, that’s got good and bad aspects. The good aspects are that it differentiates
us, it gives us some IP that’s different from commoditised products, but the downside
is that there is some technical risk associated with that proprietary approach.

For Goliath, the way that we’re addressing that is that we’re running a series of
programmes which actually are being supported by grant funding, primarily from the
Advanced Proportion Centre or APC, in order to address things like process design,
the formation design. A formation is where you take the finished cells and you actually
cycle them a few times so that you get a stabilised performance. That’s one of the
intrinsic advantages of solid state is that actually the amount of cycling that 
you need to form the cells is reduced and that’s got a fantastic benefit in terms
of reduced CapEx and reduced operating costs in terms of energy and work in progress.
So, you need a smaller inventory of cells in your production facility.

What we’re also doing is looking specifically at the UK BIC, we’ve got a programme
that we’ve just started with them, that’s the Battery Industrialisation Centre. 
That programme is called Bus 100, which is all about looking at the specific economics
of battery manufacture at their facility, making sure that we can make the initial
quantities of cells at a price point that makes sense for us all.

Finally, we’ve got a programme that’ll be starting soon which is more involved in
vendor equipment demonstration and de-risking some of the designs that we are implementing
in order to scale up manufacturing.

**Q6: Now, the space it’s very competitive, can Ilika realistically succeed against
very well-funded competitors?**

**A6**: It’s true that in particular, some of the technology development companies
in the US are very well funded, they’ve raised significantly more capital than we
have over the years. However, I don’t think this is a ‘winner takes all’ scenario,
there’s plenty of data from the existing battery sector that demonstrates there’s
a variety of solutions that are used in different applications.

So, we think we’re still in the race, we’ve got some very well differentiated and
competitive ideas around solid state and our prototype cells are offering all sorts
of benefits from an ease of manufacture perspective and a cost perspective. I think
that our solution will be very much attractive to OEMs and the sector, and that’ll
be reflected in some of the partnering news flow that we introduce in the future.

Share on:
